The Karolinska University Hospital is a teaching hospital affiliated with Karolinska Institutet in Stockholm, Sweden, with two major sites in the municipalities of Solna and Huddinge. The hospital network is the second largest in Sweden, after Sahlgrenska University Hospital.

There are 1,340 beds in Department of Hematology, Karolinska University Hospital.

During the past decade, Department of Hematology, Karolinska University Hospital conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Department of Hematology, Karolinska University Hospital" #1 sponsor was "Nordic MDS Group" with 3 trials, followed by "Alexion" with 2 trials sponsored, "Nordic Lymphoma Group" with 2 trials sponsored, "Celgene" with 1 trials sponsored and "Celgene Corporation" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Department of Hematology, Karolinska University Hospital" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Region Stockholm" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Department of Hematology, Karolinska University Hospital" are "MDS" (2 trials), "AML" (1 trials), "Chronic Myelomonocytic Leukemia" (1 trials), "DLBCL" (1 trials) and "Diffuse Large B Cell Lymphoma" (1 trials). Many other conditions were trialed in "Department of Hematology, Karolinska University Hospital" in a lesser frequency.

Most popular intervention types in "Department of Hematology, Karolinska University Hospital" are "Drug" (8 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "eculizumab" (2 trials), "Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma" (1 trials), "Azacitidine" (1 trials), "CC-5013" (1 trials) and "Erythropoetin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Department of Hematology, Karolinska University Hospital" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Department of Hematology, Karolinska University Hospital". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Department of Hematology, Karolinska University Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Department of Hematology, Karolinska University Hospital, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".